Mirum and Incyte report positive phase 2 results for FOP treatment

June 14, 2026 4:35 PM

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) and Incyte Corp. (NASDAQ: INCY) announced positive results from a phase 2 study of zilurgisertib ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found